The Relationship Between Osteoporosis and Chronic Oral Anticoagulation Therapy With Warfarin

The purpose of this study is to determine if osteoporosis is an unrecognized complication of chronic anticoagulation with warfarin.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Osteoporosis Bone Diseases Bone Diseases, Metabolic Metabolic Diseases Musculoskeletal Diseases Nutritional and Metabolic Diseases

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Staten Island University Hospital

Staten Island, New York, 10305, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients on warfarin that have had BMD within a year

Exclusion criteria

Patients on bisphosphates, SERMS, anticonvulsants, estrogens, androgens, calcitonin, hctz and thyroid hormone replacement

Treatment and study plan

Primary outcomes

Bone Density

Time frame: 5 to 10 years

bone density as measured by xray to assess bone strength nd risk of fracture

Sponsors and collaborators

Lead sponsor

Northwell Health

Other

Collaborators

Staten Island University Hospital

Registry information

Important dates

Study start: 2004
Primary completion: 2009
Study completion: 2009
First posted: Apr 24, 2008
Registry last updated: Oct 14, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed